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ABSTRACT
Background. The role of 18F-fluorodeoxyglucose positron
emission tomography with computed tomography (FDG-
PET/CT) and staging laparoscopy (SL) has increased in the
preoperative staging of gastric cancer. Dutch national
guidelines have recommended the use of FDG-PET/CT and
SL for patients with locally advanced tumors since July
2016.
Objective. The aim of this study was to evaluate the
implementation of FDG-PET/CT and SL in The
Netherlands.
Methods. Between 2011 and 2018, all patients who
underwent surgery for gastric cancer were included from
the Dutch Upper GI Cancer Audit. The use of FDG-PET/
CT and SL was evaluated before and after revision of the
Dutch guidelines. Outcomes included the number of non-
curative procedures (e.g. palliative and futile procedures)
and the association of FDG-PET/CT and SL, with waiting
times from diagnosis to the start of treatment.
Results. A total of 3310 patients were analyzed. After July
2016, the use of FDG-PET/CT (23% vs. 61%; p\ 0.001)
and SL (21% vs. 58%; p\ 0.001) increased. FDG-PET/CT
was associated with additional waiting time to neoadjuvant
therapy (4 days), as well as primary surgical treatment
(20 days), and SL was associated with 8 additional days of
waiting time to neoadjuvant therapy. Performing SL or
both modalities consecutively in patients in whom it was
indicated was not associated with the number of non-cu-
rative procedures.
Conclusion. During implementation of FDG-PET/CT and
SL after revision of the guidelines, both have increasingly
been used in The Netherlands. The addition of these
staging methods was associated with increased waiting
time to treatment. The number of non-curative procedures
did not differ after performing none, solely one, or both
staging modalities.
For patients with locally advanced gastric cancer, the
main curative treatment comprises perioperative
chemotherapy and gastrectomy.1–3 The standard initial
staging of gastric cancer consists of gastroscopy and
computed tomography (CT) of the thorax and abdomen.4
However, these modalities frequently miss distant metas-
tases or tumor invasion in adjacent structures,5–7 which are
important characteristics that limit curative treatment. As a
result, patients may undergo neoadjuvant chemotherapy
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and/or surgery without any evident survival benefit, but
with the risk of additional morbidity and short-term mor-
tality, due to surgery as well as chemotherapeutic toxicity.
There has been an increasing interest in the role of
fluorodeoxyglucose positron emission tomography with CT
(FDG-PET/CT) and staging laparoscopy (SL) in the pre-
operative staging of gastric cancer. Compared with CT
alone, FDG-PET/CT has been reported to detect additional
distant metastases in 10% of patients with locally advanced
gastric cancer, whereas SL detects peritoneal metastases in
another 19% of patients.8 If distant metastases are detected
during the diagnostic process, a more tailored treatment
can be offered, such as systemic treatment with palliative
intent. In July 2016, the Dutch national guidelines for the
diagnosis and treatment of gastric cancer have been revised
and advise FDG-PET/CT and SL for patients with locally
advanced tumors that are considered for treatment with
curative intent1; however, the consequences of these new
guidelines on patient outcomes are not yet clear. The main
potential positive effect is reduction of non-curative pro-
cedures, whereas the main possible negative effect is delay
of treatment, which is undesirable from a patient perspec-
tive. The aim of the current population-based study was to
evaluate the implementation of FDG-PET/CT and SL in
The Netherlands and its effect on non-curative resection
rates and waiting time from diagnosis to treatment.
METHODS
Study Design
This population-based observational study retrieved
anonymous data from the Dutch Upper GI Cancer Audit
(DUCA) database. DUCA is a national surgical registry of
all patients who underwent surgery for gastroesophageal
cancer since 2011. Patients in whom no surgical procedure
was performed, for example due to distant metastases
detected by FDG-PET/CT, are not registered in the DUCA
database. For Dutch hospitals performing gastroesophageal
cancer surgery, it is mandatory to provide patient-, tumor-
and surgical treatment-related data to the DUCA every
year, which is part of the Dutch Institute for Clinical
Auditing. An in-depth quality investigation of this national
audit has shown trustworthy and complete data registry.9
The current study was approved by the Scientific Com-
mittee of DUCA, and no ethical approval or informed
consent was required according to Dutch law.
Study Population
All patients who underwent any type of surgery for
gastric adenocarcinoma between 2011 and 2018 in The
Netherlands were included. Patients with inadequate stag-
ing (no diagnostic CT scan), or who underwent emergency,
prophylactic or other resection, other than gastrectomy, or
with missing data preventing the analysis of the study
outcomes (e.g. time of diagnosis), were excluded.
Diagnosis and Treatment
In The Netherlands, the diagnosis, staging, and treat-
ment of gastric cancer is advised to be performed according
to Dutch national guidelines and the 7th edition of the
American Joint Committee on Cancer TNM staging
system.1,4,10
Centralization of gastric cancer surgery has been grad-
ually introduced in The Netherlands during the study
period. As of 2013, a minimum of 20 gastrectomies per
center per year is required9,11,12; a center performing at
least that number of resections in a year is defined as a
high-volume center. The recommended staging process
consists of gastroscopy with biopsies and CT scan of the
thorax and abdomen in all patients. If there is doubt about
the depth of ingrowth, an endoscopic ultrasound (EUS) can
be performed to make a better distinction between cT1-2
and cT3-4, or to decide on whether or not to perform an
endoscopic mucosal resection (EMR)/endoscopic submu-
cosal dissection (ESD). Since July 2016, FDG-PET/CT and
SL with peritoneal lavage and cytology are advised by the
Dutch national guidelines for patients with a locally
advanced tumor detected on CT (FDG-PET/CT in patients
with C cT3 and/or cN ? tumors, and SL in patients
with C cT3 tumors).1 If no metastases are diagnosed, the
recommended curative treatment consists of surgical
resection by (sub)total gastrectomy with lymphadenectomy
according to the Japanese Gastric Cancer Treatment
Guidelines.13 All patients with resectable gastric cancer
(clinical stage[ I) are treated with perioperative
chemotherapy similar or comparable to the MAGIC or
FLOT4 trials2,3,14 if deemed fit enough. Palliative treat-
ment consists of systemic chemotherapy and palliative
resection or radiotherapy in patients with symptoms, such
as obstruction or bleeding.
Study Outcomes
The study outcomes included adherence to the national
guidelines before and after publication of the new update of
the guidelines (1 July 2016), waiting time from diagnosis to
the start of treatment, and number of non-curative proce-
dures. Treatment in adherence to the revised guidelines was
defined as the proportion of patients who underwent FDG-
PET/CT or SL who had an indication for these diagnostic
modalities as stated earlier, and the proportion of patients
not undergoing these modalities if there was no indication.
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To evaluate waiting time, the time of diagnosis was defined
as the date of the pathology report of the endoscopic
biopsies confirming the presence of gastric cancer, and the
time of treatment was defined as either the start date of
neoadjuvant therapy or the date of surgery in case of pri-
mary surgery. Since SL in clinical practice was frequently
performed during the same procedure as the planned gas-
trectomy, it was decided not to perform an analysis on
waiting time after SL for the group who underwent primary
surgery. Non-curative procedures consisted of palliative
gastrectomy (which was intended to be curative before the
start of the procedure), construction of a bypass (i.e. no
resection), or a futile procedure. In order to analyze the
effects of FDG-PET/CT and SL on the rate of non-curative
procedures, a subselection was made, including all patients
with curative intent with at least a C cT3 and/or N ? tu-
mor, as this is the indication for performing FDG-PET/CT
(C cT3 and/or N ?) or SL (C cT3) according to the cur-
rent Dutch guidelines.
Statistical Analysis
Patient-, tumor-, and treatment-related characteristics
were evaluated and described, as was the frequency of
missing values per variable. Missing values in time points
to evaluate waiting time were imputed using means of the
total cohort and other known time points during diagnostic
work-up and treatment. Baseline characteristics were
compared between patients undergoing or not undergoing
FDG-PET/CT or SL, using the Chi square test, Student’s
t test, or Mann–Whitney U test, depending on type and
distribution of the variable. Waiting time from diagnosis to
the start of treatment was visually inspected, and, because
of a non-normal distribution, was logarithmically trans-
formed before performing univariable and multivariable
linear regression analyses. In order to determine the dif-
ferences in the proportion of non-curative procedures with
or without FDG-PET/CT or SL, cross tables with Chi
square statistics were generated. All statistical analyses
were performed using SPSS version 25.0 (IBM Corpora-
tion, Armonk, NY, USA). Statistical significance was set at
p\ 0.05.
RESULTS
Study Population
In The Netherlands, 3818 patients underwent surgery for
gastric adenocarcinoma in the period 2011–2018. A total of
508 patients were excluded due to an emergency setting
(n = 165), prophylactic (n = 26) or other resection, other
than gastrectomy (n = 58), missing CT scans (n = 30),
missing time points (n = 100), or missing data (n = 129).
Of the remaining 3310 patients, 1912 did not undergo
either FDG-PET/CT or laparoscopy, 643 patients under-
went FDG-PET/CT only, 396 patients underwent solely
SL, and 359 patients underwent both diagnostic modalities
(Fig. 1). Baseline characteristics are presented in Table 1.
Patients undergoing FDG-PET/CT had more comorbidities
compared with the other groups. Patients undergoing SL
were younger, had a marginally lower body mass index
(BMI) and a more favorable American Society of Anes-
thesiologists (ASA) classification. Patients undergoing the
diagnostic modalities were more frequently referred to a
high-volume center and had more advanced tumors.
The majority of patients underwent neoadjuvant
chemotherapy (55%), 50 patients (2%) underwent neoad-
juvant chemoradiotherapy, 3 patients (\ 1%) underwent
neoadjuvant radiotherapy, and 44% of patients did not
undergo neoadjuvant treatment. In total, 86% of patients
underwent curative surgery, 4% underwent palliative sur-
gery, and in 10% no resection was performed (a futile
procedure in 7% and construction of a bypass in 3%). Total
gastrectomy was performed in 1235 patients (37%), and
subtotal gastrectomy was performed in 1749 patients
(53%). The mean (± standard deviation [SD]) waiting time
from diagnosis to the start of treatment for all patients was
36 days (± 18.9) for neoadjuvant treatment and 54 days
(± 31.7) for primary surgery.
18F-FLUORODEOXYGLUCOSE POSITRON
EMISSION TOMOGRAPHY WITH COMPUTED
TOMOGRAPHY
Before implementation of the guidelines, FDG-PET/CT
was performed in 323/1389 patients (23%) for whom this
would have been indicated according to the revised
guidelines (C cT3 and/or N ? tumors), whereas after
implementation of the guidelines 354/583 patients (61%)
underwent FDG-PET/CT (p\ 0.001) [Fig. 2]. However,
after implementation of the guidelines, the use of FDG-
PET/CT also increased in patients in whom it was not
recommended by these guidelines (17% vs. 43%).
Regarding waiting times, multivariable linear regression
analyses showed that FDG-PET/CT was associated with an
additional waiting time of 4 days (p\ 0.001) in the
patients who were treated with neoadjuvant chemotherapy.
In the group of patients who underwent primary surgery,
FDG-PET/CT was associated with 20 extra waiting days
(p\ 0.001). These results are presented in Tables 2 and 3.
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Staging Laparoscopy
Before implementation of the revised guidelines, SL
was performed in 237/1140 patients (21%) in whom this
would have been indicated according to the revised
guidelines (C cT3 tumors). This percentage increased to
58% (289/499, p\ 0.001) after implementation of the
revised guidelines (Fig. 2). Additionally, the use of SL also
increased in patients in whom there was no indication
according to the revised guidelines, after its implementa-
tion (from 8 to 32%).
SL was associated with an additional waiting time of
8 days (p\ 0.001) to the start of neoadjuvant chemother-
apy in the group of patients who received neoadjuvant
chemotherapy (Table 2).
In all patients who underwent either solely SL (n = 396)
or both modalities (n = 359), SL identified metastases or
irresectable disease in 76 patients (10%, numbers not
shown in Fig. 1), resulting in a preoperatively determined
palliative intent in these patients. In the group of patients
who had not undergone either FDG-PET/CT or SL
(n = 1912), a palliative intent of treatment was registered
in 67 patients (4%), versus 36 patients (6%) in the group of
patients who underwent solely FDG-PET/CT (n = 643).
Non-curative Surgery
For analyzing the effects of FDG-PET/CT and SL on the
number of non-curative resections as determined at the end
of the procedure, only those patients with at least a cT3
and/or N ? tumor and curative intent were selected. A
total of 1746 patients with at least a cT3 and/or N ? tumor
were treated with curative intent (Fig. 1). Of these, 225
patients (13%) were eventually registered at the end of the
surgical procedure as having undergone non-curative sur-
gery, consisting of 51 patients in whom a palliative
resection had been performed, 57 patients who received a
bypass (i.e. no resection), and 117 patients who underwent
a futile procedure. The incidence of intraoperatively
determined non-curative surgery did not differ between the
patient groups undergoing one or both of the staging
modalities (13% after none; 15% after FDG-PET/CT; 14%
after SL; 10% after both modalities; p = 0.492).
DISCUSSION
In this population-based study, the implementation of
FDG-PET/CT and SL for patients with gastric cancer in
The Netherlands, and their association with logistics and
the proportion of non-curative procedures, were evaluated.
FDG-PET/CT only
n = 643
SL only
n = 396
DUCA Dataset
n = 3818
Included patients
n = 3310
Exclusion:
• Emergency resection (n=165)
• Prophylactic resection (n=26)
• Thoracotomy or other resection (n=58)
• Missing CT-abdomen (n=30)
• Missing data (n=229)
FDG-PET/CT only and
cT3 and/or cN+ 
n = 381
SL only and cT3 
n = 264
No additional staging
n = 1912
FDG-PET/CT + SL
n = 359
FDG-PET/CT + SL 
and cT3 
n = 262
No additional staging
and >cT3 and/or cN+
n = 991
Curative intent 
n = 230
Indication for additional staging according to the guidelines (n=1898)
Curative 
n = 206
Non -curative 
n=24
Curative intent 
n = 226
Curative 
n =195
Non-curative 
n=31
Curative intent 
n = 355
Curative 
n = 303
Non -curative 
n=52
Curative intent 
n = 935
Palliative surgery* 
n = 56
Curative 
n = 817
Non-curative 
n = 118
Final surgical treatment Final surgical treatment Final surgical treatment Final surgical treatment
Palliative surgery* 
n = 26
Palliative surgery* 
n = 38
Palliative surgery* 
n=32
FIG. 1 Study flowchart. For analysis on the number of non-curative
surgeries, only patients with a curative intent of treatment, as
determined prior to surgery, were included (green outline). Final
treatment represents the final treatment that has taken place, as
determined at the end of surgery. * As determined prior to surgery.
CT computed tomography, FDG-PET/CT 18F-fluorodeoxyglucose
positron emission tomography with computed tomography, SL staging
laparoscopy
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TABLE 1 Baseline characteristics of 3310 patients who underwent surgery for gastric cancer
No additional staging
modalities [n = 1912]
FDG-PET/CT
[n = 643]
Staging
laparoscopy
[n = 396]
FDG-PET/CT and staging
laparoscopy [n = 359]
p value Missing
values (%)
Patient characteristics
Age, years
(mean ± SD)
69.9 ± 11.7 69.7 ± 11.2 65.9 ± 11.7 66.8 ± 11.1 \ 0.001 0 (0)
BMI, kg/m2
(mean ± SD)
25.4 ± 4.6 25.6 ± 4.3 24.7 ± 4.0 24.9 ± 4.4 0.003 63 (2)
Sex 0.289 0 (0)
Male 1189 (62) 421 (66) 240 (61) 217 (60)
Female 723 (38) 222 (35) 156 (39) 142 (40)
ASA classification 0.008 17 (1)
I–II 1270 (67) 418 (65) 296 (75) 251 (70)
III–IV 629 (33) 221 (35) 100 (25) 108 (30)
Comorbidities 1557 (81) 544 (85) 308 (78) 300 (84) 0.035 0 (0)
Cardiaca 609 (32) 232 (36) 85 (22) 103 (29) \ 0.001 0 (0)
Vascularb 794 (42) 285 (44) 151 (38) 150 (42) 0.270 0 (0)
Diabetes mellitus 354 (19) 113 (18) 59 (15) 69 (19) 0.339 0 (0)
Pulmonaryc 315 (17) 121 (19) 44 (11) 59 (16) 0.013 0 (0)
Malignancyd 302 (16) 147 (23) 61 (16) 67 (19) 0.001 65 (2)
Previous abdominal or
thoracic surgery
770 (40) 280 (44) 150 (38) 142 (40) 0.292 5 (\ 1)
Tumor characteristics
cT stage \ 0.001 0 (0)
\ cT3 583 (42) 183 (38) 77 (23) 5818 (30)
C cT3e 810 (58) 303 (62) 264 (77) 262 (82)
cTx 770 (23) 196 (20) 94 (13) 676 (27)
cN stage \ 0.001 0 (0)
N0 1045 (63) 312 (56) 162 (45) 137 (40)
N? 627 (38) 249 (44) 197 (55) 208 (60)
Nx 373 (11) 96 (10) 51 (7) 322 (13)
cM stage \ 0.001 0 (0)
M0 1790 (99) 594 (67) 347 (93) 317 (91)
M1 22 (1) 20 (3) 28 (8) 32 (9)
Mx 160 (5) 39 (4) 31 (4) 129 (5)
Tumor location \ 0.001 41 (1)
Fundus 104 (6) 78 (12) 29 (7) 38 (11)
Corpus 577 (31) 213 (34) 148 (37) 128 (36)
Antrum 858 (46) 226 (36) 139 (35) 127 (36)
Pylorus 154 (8) 46 (7) 33 (8) 28 (8)
Whole stomach 89 (5) 43 (7) 40 (10) 26 (7)
Residual stomach 97 (5) 30 (5) 7 (2) 26 (7)
Referral status \ 0.001 280 (9)
Diagnosis in the
treatment hospital
635 (37) 168 (29) 108 (28) 69 (20)
Diagnosis in another
hospital
1075 (63) 420 (71) 274 (72) 281 (80)
Hospital volume \ 0.001 0 (0)
\ 20 gastrectomies 535 (28) 122 (19) 41 (10) 20 (6)
20–40 gastrectomies 734 (38) 269 (42) 174 (44) 137 (38)
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After revision of the national guidelines in July 2016,
which now recommend FDG-PET/CT and SL in patients
with locally advanced tumors, significantly more FDG-
PET/CTs and SLs were performed. Remarkably, the
increase in PET/CT and SL was not only observed in
patients with an indication for these modalities according
to the guidelines but also in patients without a predefined
indication. This may be due to treating physicians
becoming more aware of the possible value of FDG-PET/
CT and SL, and therefore also requesting these procedures
in other patients who they regard at increased risk for
metastases. Referral to a high-volume center more fre-
quently resulted in performing FDG-PET/CT and SL,
which was associated with a significantly longer waiting
time from diagnosis to the start of treatment. Performing
SL or both modalities consecutively may not be associated
with the incidence of non-curative surgery.
Although FDG-PET/CT and SL were more frequently
performed for locally advanced gastric tumors, approxi-
mately 40% of the patients in whom this was indicated still
did not undergo FDG-PET/CT and SL in the current study.
This might be explained by a lag time between publication
of guidelines and their adoption in clinical practice.15
Several general barriers for the adoption of new guidelines
have been identified and reported, such as lack of aware-
ness, lack of agreement with the new guidelines, and lack
of outcome expectancy.15 Interventions to promote the
implementation of research findings include educational
outreach visits.16 As part of the PLASTIC study,17 a
prospective observational cohort study in The Netherlands
that evaluated the impact and cost effectiveness of FDG-
PET/CT and SL in addition to initial staging (CT and
gastroscopy) in patients with locally advanced gastric
cancer, these educational visits started in August 2017.
Other factors that have been reported to contribute to slow
implementation are the qualities of the guidelines (such as
compatibility with existing beliefs and values, or com-
plexity), characteristics of the health care practice setting
(including legal and financial aspects), and characteristics
of the healthcare professional (e.g. age).18 Besides delayed
adoption of the revised guidelines in clinical practice, there
might be other factors contributing to not performing FDG-
PET/CT or SL in appropriate patients. The general reasons
for refraining from SL may include older age (as older
patients are frailer and have more comorbidities), tumors
causing complications (e.g. obstruction, hemorrhage, per-
foration), and a history of prior upper abdominal surgery
with severe adhesions.19,20
TABLE 1 (continued)
No additional staging
modalities [n = 1912]
FDG-PET/CT
[n = 643]
Staging
laparoscopy
[n = 396]
FDG-PET/CT and staging
laparoscopy [n = 359]
p value Missing
values (%)
[ 40 gastrectomies 643 (34) 252 (39) 181 (46) 202 (56)
Data are expressed as n (%) unless otherwise specified
Percentages may not add up to 100% due to rounding
ASA American Society of Anesthesiologists; BMI body mass index; FDG-PET/CT 18F-fluorodeoxyglucose positron emission tomography with
computed tomography; SD standard deviation; PTCA percutaneous transluminal coronary angioplasty; CABG coronary artery bypass graft
aPatients with a history of angina pectoris, myocardial infarction, congestive heart failure, PTCA, CABG, valve insufficiency or replacement,
heart rhythm disorders, cardiomyopathy, status after heart transplant
bPatients with hypertension of peripheral vascular disease
cPatients with asthma or chronic obstructive pulmonary disease
dCurrently or previously treated malignancy other than gastric carcinoma
eOf whom 1495 patients underwent curative treatment
0
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20
30
40
50
60
70
80
90
100
PET in whom it was indicated 
( cT3/N+)
Laparoscopy in whom it was indicated 
( cT3)
Before new guidelines After new guidelines
23%
61% 58%
21%
p<0.001 p<0.001
FIG. 2 Use of FDG-PET/CT and SL before and after
implementation of the revised national guidelines. FDG-PET/CT
18F-fluorodeoxyglucose positron emission tomography with
computed tomography, SL staging laparoscopy
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In the current study, 32–43% of patients underwent
FDG-PET/CT or SL, although there was no indication
according to the current guidelines. In this context, it is
important to note that clinical staging of gastric cancer is
known to be inaccurate.5,6,21–23 Several reasons to perform
additional diagnostics in patients with lower tumor stages
may exist, such as excessive weight loss or previous
malignancy, which might increase the clinical suspicion of
occult metastases. Nevertheless, considering additional
diagnostics in patients for whom there is no accepted
indication according to guidelines should be performed
with care as longer waiting times impair quality of life and
might allow for tumor progression. Other possible disad-
vantages include higher diagnostic health care costs,
incidental findings that require further investigations, and
possible morbidity due to SL. To slightly elaborate on the
costs, an FDG-PET/CT costs €1200 on average24 and an
SL costs €900 on average, based on the minute price of the
operating room (including operating room, nurses, surgeon,
anesthesiologist, overheads).25 However, we await the
results of the PLASTIC study in order to make statements
on the economic aspects.
Although literature on whether or not high-volume
centers follow directives more frequently is not available,
the current study concluded that FDG-PET/CT and SL
were more frequently performed in higher-volume centers.
It has been previously reported that centralization of gastric
cancer care in high-volume centers in The Netherlands
resulted in improved postoperative outcomes.11,26 The
results of the current study confirm that the referral of
patients to high-volume centers may result in better health
care by providing clinical care in accordance with the
guidelines.
TABLE 2 Waiting time to neoadjuvant treatment
Univariable
Mean waiting time (days, SD)
Multivariablea
Bb 95% CI Additional days p value
Modalities
None 28.9 (± 15.9) Ref – – –
FDG-PET/CT 36.0 (± 18.5) 0.19 0.07–0.31 4 0.001
Staging laparoscopy 37.5 (± 15.0) 0.34 0.24–0.45 8 \ 0.001
Both modalities 47.0 (± 23.9) 0.52 0.41–0.62 14 \ 0.001
Multivariable linear regression analyses on the influence of patient, tumor, and diagnostic characteristics on waiting time from diagnosis to the
start of neoadjuvant treatment (n = 1808)
aAdjusted for age, BMI, weight loss, comorbidities (overall, cardiac, pulmonary, previous malignancy, previous abdominal surgery), ASA,
referral status, location of tumor, cT stage, cN stage, hospital volume
bIntercept = 3.008 (20 days)
ASA American Society of Anesthesiologists; FDG-PET/CT 18F-fluorodeoxyglucose positron emission tomography with computed tomography;
SD standard deviation; CI confidence interval; BMI body mass index
TABLE 3 Waiting time to surgical treatment
Univariable
Mean waiting time (days, SD)
Multivariablea
Bb 95% CI Additional days p value
FDG-PET/CT
No 50.2 (± 28.3) Ref – – –
Yes 65.1 (± 38.2)c 0.28 0.20–0.36 20 \ 0.001
Multivariable linear regression analyses on the influence of patient, tumor, and diagnostic characteristics on waiting time from diagnosis to
primary surgical treatment with curative intent (n = 1332)
aAdjusted for age, BMI, weight loss, comorbidities (overall, cardiac, pulmonary, previous malignancy, previous abdominal surgery), ASA,
referral status, location of tumor, cT stage, cN stage, hospital volume
bIntercept = 4.129 (62 days)
cSignificantly different
ASA American Society of Anesthesiologists; FDG-PET/CT 18F-fluorodeoxyglucose positron emission tomography with computed tomography;
SD standard deviation; CI confidence interval; BMI body mass index
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Baseline waiting times found in the current study fell
within the indicated waiting times advised and aimed at by
Dutch guidelines.27 In addition, baseline waiting times
were comparable with previously reported median waiting
times of 4.6 weeks to the start of neoadjuvant treatment
and 6 weeks to primary surgery.28 Performing FDG-PET/
CT or SL was associated with a significantly prolonged
waiting time from diagnosis to the start of treatment, both
for neoadjuvant treatment (although clinically less rele-
vant) and primary surgical treatment. Patients undergoing
primary surgery are usually older and have several
comorbidities, and are therefore not deemed fit enough for
chemotherapy.29,30 It is possible that in these patients,
additional findings are more frequently detected on FDG-
PET/CT or during SL, for which further diagnostics are
required. Other confounding factors might also contribute
to increasing waiting times. For example, generally
increasing waiting times due to pressure on the health care
system and centralization of gastric cancer treatment might
play a role as patients had to be referred to tertiary centers
more often over the years. Regardless of the potential
causes, it is questionable what the clinical relevance of the
reported extended waiting times is, since previous studies
suggested that an additional waiting time of some weeks
does not lead to decreased long-term survival.28
Smyth et al.8 conducted a study of 113 locally advanced
gastric cancer patients (cT3-4) and reported a 10% reduc-
tion in the number of futile procedures after performing an
FDG-PET/CT, and a decrease of 19% after SL. Findlay
et al.31 performed a study of 279 gastric cancer patients and
reported unsuspected metastases found with FDG-PET/CT
in 7% of patients. In the study from Bosch et al.,32 addi-
tional metastases were detected in 16% of 105 patients.
These findings on FDG-PET/CT resulted in a treatment
change from curative to palliative intent, and prevention of
futile surgery with accompanying morbidity in these
patients. Unfortunately, as the DUCA does not register
patients in whom surgery was omitted based on findings on
FDG-PET/CT, the results of our study can neither confirm
nor refute these results. Regarding the detection of meta-
static or irresectable disease in the case of SL, literature on
the yield of SL varies from detection rates of 19–52%.
Furthermore, the percentage found in this study (10%) does
not completely support these previously published num-
bers.8,33–35 An explanation for this might be that peritoneal
lavage is also included in the aforementioned studies and
scored as positive SL, whereas in the current dataset, nei-
ther information on whether peritoneal lavage has been
performed nor outcomes of the SL are registered. In our
study, no differences were found in the number of intra-
operatively determined non-curative procedures when
comparing the performance of no, solely one, or both
staging modalities; however, it should be noted that this
was analyzed during the implementation phase of the
guideline.
Several other limitations apply to the current study.
First, no data on the outcomes of FDG-PET/CT are avail-
able and patients not undergoing surgery are not registered
in the DUCA as it is a surgical registry, which could have
resulted in underestimation of the proportions reported in
this study. Therefore, it is not possible to draw firm con-
clusions on the treatment changes based on FDG-PET/CT
findings. Second, the dataset used for this study does not
contain histopathology data, while several studies report
that FDG-PET/CT may specifically be useful in patients
with specific tumor biology or characteristics, such as
intestinal type or poorly differentiated adenocarcino-
mas.6,23 For these reasons, the results of the PLASTIC trial,
also evaluating histopathology data, are awaited.17
CONCLUSION
This population-based study demonstrates that FDG-
PET/CT and SL have increasingly been used in patients
with locally advanced gastric tumors in The Netherlands,
mainly in high-volume centers, at the expense of prolonged
waiting times from diagnosis to the start of treatment. No
differences in the proportion of non-curative procedures
were found when performing SL or both modalities con-
secutively in the patients who had an indication. However,
it should be noted that no firm conclusions can be made on
solely performing FDG-PET/CT, and therefore the results
of the PLASTIC study should be awaited. Future studies
should focus on patient selection for FDG-PET/CT and SL
and the potential consequences of prolonged waiting times.
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